Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22425951 | 0.91 | MALT1 (0.35) | MALT1HTR2CSLC6A4P2RX3 | |
| SCHEMBL22252388 | 0.86 | LMNA (0.36) | MALT1P2RX3 | |
| SCHEMBL31161680 | 0.81 | TYK2 (0.40) | MALT1P2RX3 | |
| SCHEMBL31161633 | 0.81 | TYK2 (0.40) | MALT1P2RX3 | |
| SCHEMBL22252368 | 0.79 | TYK2 (0.33) | MALT1 | |
| SCHEMBL22252471 | 0.79 | TYK2 (0.33) | MALT1 | |
| SCHEMBL22252611 | 0.79 | MALT1 (0.31) | MALT1AAK1 | |
| SCHEMBL22273062 | 0.79 | TYK2 (0.33) | MALT1 | |
| SCHEMBL22252334 | 0.79 | TYK2 (0.33) | MALT1 | |
| SCHEMBL16259910 | 0.78 | BRD9 (0.43) | MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250188093-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2025-06-12 | — | — | US | disclosed |
| CN-119604512-A | TYK2 inhibitor and application thereof | 阿鲁米斯股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4493281-A1 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| EP-4493562-A1 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-113811534-B | TYK2 inhibitors and uses thereof | 阿鲁米斯公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230357273-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230357273-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC | 2023-11-09 | — | — | US | disclosed |
| WO-2023178235-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178235-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178234-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3938369-A1 | TYK2 INHIBITORS AND USES THEREOF | Esker Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11174264-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020154474-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | MALT1 153/4885HTR2C 2342/4885SLC6A4 4299/4885 |
| US-11174264-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | MALT1 636/4885HTR2C 3262/4885SLC6A4 4778/4885 |
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | MALT1 153/4885HTR2C 2342/4885SLC6A4 4299/4885 |
| US-20250188093-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | MALT1 153/4885HTR2C 2342/4885SLC6A4 4299/4885 |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MALT1 636/4885HTR2C 3262/4885SLC6A4 4778/4885 |
| US-20230357273-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | MALT1 226/4885HTR2C 2958/4885SLC6A4 4629/4885 |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | MALT1 153/4885HTR2C 2342/4885SLC6A4 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.